

Population Research Committee (PRC)

Supplementary Terms of Reference

1 Remit: to be responsible for the oversight, development, review, funding and management of the Cancer Research UK portfolio in population sciences, covering all aspects of:

- (i) Clinical and public health epidemiology (excluding primary and secondary prevention studies involving medical interventions e.g. vaccines and chemo-prevention¹)
- (ii) Educational and behavioural research in the areas of prevention, screening and early diagnosis

The Committee will also consider applications for funding for the following:

- (iii) Proposals considering clinical trials methodologies or statistics
- (iv) Proposals considering secondary effects of treatment

The PRC will work with the NCRI and the NCRN including the site specific and cross-cutting Clinical Studies (Development) Groups.

2 Additional Terms:

- 2.1 To oversee all aspects of Cancer Research UK's funding for small grants, projects, programmes and Centres in the area of population sciences, excluding clinical trials and programmes and projects falling within the remits of the Biological Sciences, Clinical Trials Awards and Advisory; Clinical and Translational; Biomarkers and Imaging Discovery and Development Committees.
- 2.2 To keep abreast of, and where relevant address, external factors such as government policies which impact on Cancer Research UK's PRC portfolio.
- 2.3 To provide input into the Training & Career Development Board by identification of training needs and opportunities particularly in relation to specific educational, epidemiological, behavioural and public health fellowships.
- 2.4 To act as a parent committee to the Tobacco Advisory Group and to delegate to them the authority to take decisions and make awards within their budgets and areas of responsibility.
- 2.5 To receive the minutes (or other record) of the Tobacco Advisory Group Sub-Committee and overview their decisions particularly in the light of strategic implications or major impact on population research.

3 Meetings: the committee will meet twice a year.

¹ Which are overseen by the Drug Development Office or Clinical Trials Awards and Advisory Committee.